Disitamab (RC48-0) is a humanized monoclonal antibody targeting HER2. Disitamab can be used in the synthesis of antibody-drug conjugates (ADCs), Disitamab vedotin (Disitamab vedotin (HY-P9985))[1].
in vivo
Disitamab (27 mg/kg; i.v.; once; 5 mL/kg) shows no significant toxicity in monkeys[1].
IC 50
HER2
References
[1] Jiang J, et al. Preclinical safety profile of disitamab vedotin:a novel anti-HER2 antibody conjugated with MMAE. Toxicol Lett. 2020;324:30-37. DOI:10.1016/j.toxlet.2019.12.027